trending Market Intelligence /marketintelligence/en/news-insights/trending/tsTmbfgaBSSGxjSIpoOICw2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

In this list

Australia's Exopharm raises A$7M in IPO

COVID-19’s Impact on the Capital Markets: Identifier Issuance for Municipal Securities Sinks, but Corporate Requests Stable

How 37 Years of Default Data Can Prepare Us for the COVID-19 Fallout

How 37 Years of Default Data Can Prepare Us for the COVID-19 Fallout

IoT and AI Aid Critical Event Management to Battle COVID-19, but Deployment could Raise Privacy Concerns


Australia's Exopharm raises A$7M in IPO

Australia's Exopharm Ltd. raised A$7 million in its IPO.

The Melbourne-based developer of regenerative medicines sold 35 million shares at 20 Australian cents apiece. The shares are expected to start trading Dec. 18 on the ASX.

Exopharm said proceeds from the IPO will go toward its development program, which is focused on product candidates Plexaris and Exomeres, which are exosomes derived from human platelets and adult stem cells, respectively.

Exopharm expects to market Plexaris for indications such as wound healing, dry age-related macular degeneration and osteoarthritis. The company is currently testing Plexaris and Exomeres in animal models.